Irving Kirsch

Last updated
Irving Kirsch
Prof-Kirsch-02a-1.jpg
Born (1943-03-07) March 7, 1943 (age 80)
Known forPlacebo research
Scientific career
Fields Psychiatry

Irving Kirsch (born March 7, 1943) is an American psychologist and academic. He is the Associate Director of the Program in Placebo Studies and a lecturer in medicine at the Harvard Medical School and Beth Israel Deaconess Medical Center. [1] He is also professor emeritus of psychology at the Universities of Hull and Plymouth in the United Kingdom, and the University of Connecticut in the United States. [2] [3] Kirsch is a leading researcher within the field of placebo studies who is noted for his work on placebo effects, antidepressants, expectancy, and hypnosis. He is the originator of response expectancy theory, and his analyses of clinical trials of antidepressants have influenced official treatment guidelines in the United Kingdom. He is the author of the 2009 book The Emperor's New Drugs , which argued most antidepressant medication is effective primarily due to placebo effects.

Contents

Biography

The son of Jewish immigrants from Poland and Russia, Kirsch was born in New York City on March 7, 1943. Kirsch received his PhD in psychology from the University of Southern California in 1975. While a graduate student, he produced, in conjunction with the National Lampoon, a hit single and subsequent record album entitled The Missing White House Tapes , which were crafted by doctoring tape recordings of Richard Nixon’s speeches and press conferences during the Watergate hearings. The album was nominated for a Grammy award as Best Comedy Recording in 1974.

In 1975, Kirsch joined the psychology department at the University of Connecticut, where he worked until 2004, when he became a professor of psychology at the University of Plymouth. He moved to the University of Hull in 2007 and joined the faculty of the Harvard Medical School in 2011. Kirsch has authored or edited 10 books and more than 200 scientific journal articles and book chapters. [4]

Theories and research

Response expectancy theory

Kirsch’s response expectancy theory is based on the idea that what people experience depends partly on what they expect to experience. [5] According to Kirsch, this is the process that lies behind the placebo effect and hypnosis. The theory is supported by research showing that both subjective and physiological responses can be altered by changing people’s expectancies. [6] The theory has been applied to understanding pain, depression, anxiety disorders, asthma, addictions, and psychogenic illnesses.

Research on antidepressants

Kirsch’s analysis of the effectiveness of antidepressants was an outgrowth of his interest in the placebo effect. His first meta-analysis was aimed at assessing the size of the placebo effect in the treatment of depression. [7] The results not only showed a sizeable placebo effect, but also indicated that the drug effect was surprisingly small. This led Kirsch to shift his interest to evaluating the antidepressant drug effect.

The controversy surrounding this analysis led Kirsch to obtain files from the U.S. Food and Drug Administration (FDA) containing data from trials that had not been published, as well as those data from published trials. Analyses of the FDA data showed the average size effect of antidepressant drugs to be equal to 0.32, clinically insignificant according to the National Institute for Health and Clinical Excellence (NICE) 2004 guidelines, requiring Cohen's d to be no less than 0.50. [8] No evidence was cited to support this cut-off and it was criticised for being arbitrary; [9] NICE removed the specification of criteria for clinical relevance in its 2009 guidelines. [10] [11]

Kirsch challenges the chemical-imbalance theory of depression, writing "It now seems beyond question that the traditional account of depression as a chemical imbalance in the brain is simply wrong." [12] In 2014, in the British Psychological Society's Research Digest, Christian Jarrett included Kirsch's 2008 antidepressant placebo effect study in a list of the 10 most controversial psychology studies ever published. [13]

In September 2019 Irving Kirsch published a review in BMJ Evidence-Based Medicine, which concluded that antidepressants are of little benefit in most people with depression and thus they should not be used until evidence shows their benefit is greater than their risks. [14]

Research on hypnosis

Kirsch has focused some of his research on the topic of hypnosis. The basis of his hypnosis theory is that placebo effects and hypnosis share a common mechanism: response expectancy. Kirsch's idea on this topic is that the effects of both hypnosis and placebos are based upon the beliefs of the participant. [15] He has characterized clinical hypnosis as a "nondeceptive placebo." [16]

See also

Related Research Articles

<span class="mw-page-title-main">Antidepressant</span> Class of medication used to treat depression and other conditions

Antidepressants are a class of medications used to treat major depressive disorder, anxiety disorders, chronic pain, and addiction.

<span class="mw-page-title-main">Cognitive behavioral therapy</span> Therapy to improve mental health

Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to reduce symptoms of various mental health conditions, primarily depression and anxiety disorders. Cognitive behavioral therapy is one of the most effective means of treatment for substance abuse and co-occurring mental health disorders. CBT focuses on challenging and changing cognitive distortions and their associated behaviors to improve emotional regulation and develop personal coping strategies that target solving current problems. Though it was originally designed to treat depression, its uses have been expanded to include many issues and the treatment of many mental health conditions, including anxiety, substance use disorders, marital problems, ADHD, and eating disorders. CBT includes a number of cognitive or behavioral psychotherapies that treat defined psychopathologies using evidence-based techniques and strategies.

<span class="mw-page-title-main">Major depressive disorder</span> Mental disorder involving persistent low mood, low self-esteem, and loss of interest

Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Introduced by a group of US clinicians in the mid-1970s, the term was adopted by the American Psychiatric Association for this symptom cluster under mood disorders in the 1980 version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), and has become widely used since.

<span class="mw-page-title-main">Hypnosis</span> State of increased receptivity to suggestion and direction

Hypnosis is a human condition involving focused attention, reduced peripheral awareness, and an enhanced capacity to respond to suggestion.

Hypnotherapy is a type of mind–body intervention in which hypnosis is used to create a state of focused attention and increased suggestibility in the treatment of a medical or psychological disorder or concern.

<span class="mw-page-title-main">Placebo</span> Substance or treatment of no therapeutic value

A placebo is a substance or treatment which is designed to have no therapeutic value. Common placebos include inert tablets, inert injections, sham surgery, and other procedures.

<span class="mw-page-title-main">Sertraline</span> Antidepressant (SSRI class) medication

Sertraline, sold under the brand name Zoloft among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. The efficacy of sertraline for depression is similar to that of other antidepressants, and the differences are mostly confined to side effects. Sertraline is better tolerated than the older tricyclic antidepressants, and it may work better than fluoxetine for some subtypes of depression. Sertraline is effective for panic disorder, social anxiety disorder, generalized anxiety disorder (GAD), and obsessive–compulsive disorder (OCD). However, for OCD, cognitive behavioral therapy, particularly in combination with sertraline, is a better treatment. Although approved for post-traumatic stress disorder (PTSD), sertraline leads to only modest improvement in this condition. Sertraline also alleviates the symptoms of premenstrual dysphoric disorder (PMDD) and can be used in sub-therapeutic doses or intermittently for its treatment.

In a blind or blinded experiment, information which may influence the participants of the experiment is withheld until after the experiment is complete. Good blinding can reduce or eliminate experimental biases that arise from a participants' expectations, observer's effect on the participants, observer bias, confirmation bias, and other sources. A blind can be imposed on any participant of an experiment, including subjects, researchers, technicians, data analysts, and evaluators. In some cases, while blinding would be useful, it is impossible or unethical. For example, it is not possible to blind a patient to their treatment in a physical therapy intervention. A good clinical protocol ensures that blinding is as effective as possible within ethical and practical constraints.

<span class="mw-page-title-main">Bupropion</span> Substituted cathinone medication mainly used for depression and smoking cessation

Bupropion, sold under the brand name Wellbutrin among others, is an atypical antidepressant primarily used to treat major depressive disorder and to support smoking cessation. It is also popular as an add-on medication in the cases of "incomplete response" to the first-line selective serotonin reuptake inhibitor (SSRI) antidepressant. Bupropion has several features that distinguish it from other antidepressants: it does not usually cause sexual dysfunction; it is not associated with weight gain and sleepiness, and it is more effective than SSRIs at improving symptoms of hypersomnia and fatigue. Bupropion, particularly the immediate release formulation, carries a higher risk of seizure than many other antidepressants, hence caution is recommended in patients with a history of seizure disorder.

<span class="mw-page-title-main">Duloxetine</span> Antidepressant medication used also for treatment of anxiety and chronic pain

Duloxetine, sold under the brand name Cymbalta among others, is a medication used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, neuropathic pain and central sensitization. It is taken by mouth.

A nocebo effect is said to occur when negative expectations of the patient regarding a treatment cause the treatment to have a more negative effect than it otherwise would have. For example, when a patient anticipates a side effect of a medication, they can experience that effect even if the "medication" is actually an inert substance. The complementary concept, the placebo effect, is said to occur when positive expectations improve an outcome. The nocebo effect is also said to occur in someone who falls ill owing to the erroneous belief that they were exposed to a toxin, e.g. SARS-CoV-2 vaccine adulterants, or to a physical phenomenon they believe is harmful, such as EM radiation.

<span class="mw-page-title-main">Psychodynamic psychotherapy</span> Form of psychoanalysis and/or depth psychology

Psychodynamic psychotherapy and psychoanalytic psychotherapy are two categories of psychological therapies. Their main purpose is revealing the unconscious content of a client's psyche in an effort to alleviate psychic tension, which is inner conflict within the mind that was created in a situation of extreme stress or emotional hardship, often in the state of distress. The terms "psychoanalytic psychotherapy" and "psychodynamic psychotherapy" are often used interchangeably, but a distinction can be made in practice: though psychodynamic psychotherapy largely relies on psychoanalytical theory, it employs substantially shorter treatment periods than traditional psychoanalytical therapies. Psychodynamic psychotherapy is evidence-based; the effectiveness of psychoanalysis and its relationship to facts is disputed.

<span class="mw-page-title-main">Agomelatine</span> Atypical antidepressant classified primarily as a melatonin receptor agonist

Agomelatine, sold under the brand names Valdoxan and Thymanax, among others, is an atypical antidepressant most commonly used to treat major depressive disorder and generalized anxiety disorder. One review found that it is as effective as other antidepressants with similar discontinuation rates overall but less discontinuations due to side effects. Another review also found it was similarly effective to many other antidepressants.

<span class="mw-page-title-main">Esketamine</span> Dissociative medication

Esketamine, also known as (S)-ketamine or S(+)-ketamine, is the S(+) enantiomer of ketamine, is a dissociative hallucinogen drug used as a general anesthetic and as an antidepressant for treatment of depression. It is sold under the brand names Spravato, Ketanest, among others. Esketamine is the active enantiomer of ketamine in terms of NMDA receptor antagonism and is more potent than racemic ketamine.

Management of depression is the treatment of depression that may involve a number of different therapies: medications, behavior therapy, psychotherapy, and medical devices.

<span class="mw-page-title-main">Selective serotonin reuptake inhibitor</span> Class of antidepressant medication

Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions.

<span class="mw-page-title-main">Ideomotor phenomenon</span> Concept in hypnosis and psychological research

The ideomotor phenomenon is a psychological phenomenon wherein a subject makes motions unconsciously. Also called ideomotor response and abbreviated to IMR, it is a concept in hypnosis and psychological research. It is derived from the terms "ideo" and "motor". The phrase is most commonly used in reference to the process whereby a thought or mental image brings about a seemingly "reflexive" or automatic muscular reaction, often of minuscule degree, and potentially outside of the awareness of the subject. As in responses to pain, the body sometimes reacts reflexively with an ideomotor effect to ideas alone without the person consciously deciding to take action. The effects of automatic writing, dowsing, facilitated communication, applied kinesiology, and ouija boards have been attributed to the phenomenon.

<i>The Emperors New Drugs</i>

The Emperor's New Drugs – Exploding the Antidepressant Myth is a 2009 book by Irving Kirsch, arguing that the chemical imbalance theory of depression is wrong and that antidepressants have little or no direct effect on depression but, because of their common or serious side-effects, they are powerful active placebos.

Steven D. Hollon is an American psychologist, academic and researcher. He is the Gertrude Conaway Vanderbilt Professor of Psychology at Vanderbilt University.

Michael Pascal Hengartner is an academic psychologist at the Zurich University of Applied Sciences who has published on the subject of antidepressants and in other areas. In 2022, he published a book called Evidence-Biased Antidepressant Prescription: Overmedicalisation, Flawed Research, and Conflicts of Interest. He has also published with other notable researchers such as Joanna Moncrieff and Irving Kirsch.

References

  1. "Our team". Program in Placebo Studies & Therapeutic Encounter (PiPS).
  2. "Irving Kirsch". University of Plymouth, School of Psychology. Archived from the original on 2016-09-24. Retrieved 2014-11-28.
  3. "Irving Kirsch". University of Connecticut, Dept. Psychology. Archived from the original on 2010-06-24. Retrieved 2014-02-18.
  4. "Irving Kirsch Biography." Integrative Medicine & Health 2012. Web. 26 Mar. 2012.
  5. Kirsch, I 1985.
  6. Kirsch I, ed. (1999). How expectancies shape experience. Washington DC: American Psychological Association. p. 431. ISBN   1-55798-586-3.
  7. Kirsch I, Sapirstein G (1998-06-26). "Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication". Prevention and Treatment. 1 (2): Article 0002a. doi:10.1037/1522-3736.1.1.12a. Archived from the original on 1998-07-15.
  8. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (February 2008). "Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration". PLOS Medicine. 5 (2): e45. doi: 10.1371/journal.pmed.0050045 . PMC   2253608 . PMID   18303940.
  9. Turner, Erick H; Rosenthal, Robert (8 March 2008). "Efficacy of antidepressants". BMJ. 336 (7643): 516–517. doi:10.1136/bmj.39510.531597.80. PMC   2265347 . PMID   18319297.
  10. Cuijpers, Pim; Turner, Erick H.; Koole, Sander L.; van Dijke, Annemiek; Smit, Filip (May 2014). "What is the Threshold for a Clinically Relevant Effect? The Case of Major Depressive Disorders". Depression and Anxiety. 31 (5): 374–378. doi: 10.1002/da.22249 . PMID   24677535. S2CID   205736292.
  11. Moncrieff, Joanna; Kirsch, Irving (1 July 2015). "Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences". Contemporary Clinical Trials. 43: 60–62. doi: 10.1016/j.cct.2015.05.005 . ISSN   1551-7144. PMID   25979317.
  12. Kirsch, Irving (2010). The Emperor's New Drugs: Exploding the Antidepressant Myth. Basic Books. pp.  80. ISBN   978-0-465-02016-4.
  13. Jarrett, Christian (19 September 2014). "The 10 most controversial psychology studies ever published". Research Digest. British Psychological Society. Retrieved 7 October 2014.
  14. Jakobsen, JC; Gluud, C; Kirsch, I (25 September 2019). "Should antidepressants be used for major depressive disorder?". BMJ Evidence-Based Medicine. 25 (4): bmjebm-2019-111238. doi: 10.1136/bmjebm-2019-111238 . PMC   7418603 . PMID   31554608.
  15. Kirsch , Irving (1999). "Hypnosis and Placebos: Response Expectancy as a Mediator of Suggestion Effects" (PDF). Anales de Psicología. 15 (1): 99–110.
  16. Kirsch I (October 1994). "Clinical hypnosis as a nondeceptive placebo: empirically derived techniques". American Journal of Clinical Hypnosis. 37 (2): 95–106. doi:10.1080/00029157.1994.10403122. PMID   7992808.

Selected bibliography